Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Masaru Matsuda Sells 40,638 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 40,638 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.28, for a total transaction of $1,027,328.64. Following the completion of the transaction, the insider owned 110,003 shares in the company, valued at approximately $2,780,875.84. This trade represents a 26.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Masaru Matsuda also recently made the following trade(s):

• On Monday, December 1st, Masaru Matsuda sold 1,657 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $30.23, for a total transaction of $50,091.11.
• On Wednesday, November 19th, Masaru Matsuda sold 2,550 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $28.29, for a total transaction of $72,139.50.

Arcutis Biotherapeutics Stock Performance

Arcutis Biotherapeutics stock opened at $26.08 on Thursday. Arcutis Biotherapeutics, Inc. has a fifty-two week low of $11.13 and a fifty-two week high of $31.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The stock has a market cap of $3.19 billion, a P/E ratio of -72.44 and a beta of 1.70. The firm’s fifty day moving average price is $28.23 and its 200-day moving average price is $22.43.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of large investors have recently made changes to their positions in ARQT. Independent Advisor Alliance increased its position in Arcutis Biotherapeutics by 25.1% during the 4th quarter. Independent Advisor Alliance now owns 25,303 shares of the company’s stock valued at $735,000 after purchasing an additional 5,069 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter valued at about $414,000. Trek Financial LLC bought a new position in Arcutis Biotherapeutics in the fourth quarter worth about $540,000. Ballentine Partners LLC bought a new stake in Arcutis Biotherapeutics during the 4th quarter valued at approximately $307,000. Finally, RFG Advisory LLC purchased a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $1,577,000.

Wall Street Analysts Forecast Growth

ARQT has been the topic of a number of recent research reports. The Goldman Sachs Group increased their price target on shares of Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Mizuho upped their price objective on shares of Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. Needham & Company LLC boosted their price target on shares of Arcutis Biotherapeutics from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Zacks Research cut Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $29.20.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Neutral Sentiment: Short-interest report shows effectively 0 shares short as of Feb. 3 — the data appears anomalous (increase listed as NaN and a 0.0-day days-to-cover). This reading is unlikely to be meaningful for near-term price direction.
• Negative Sentiment: Multiple insider sales totaling roughly 46,700 shares and ~ $1.19M in proceeds were disclosed (early Feb). While insiders still hold large positions, the coordinated sales by senior executives and a director increase selling pressure and may amplify negative sentiment:
  • Larry Todd Edwards sold 2,052 shares at ~$25.50 (≈ $52,326). Larry Todd Edwards Form 4
  • Director Howard G. Welgus sold 10,000 shares at ~$25.05 (≈ $250,500). Howard Welgus Form 4
  • CFO Latha Vairavan sold 1,320 shares at ~$25.50 (≈ $33,660). Latha Vairavan Form 4
  • Todd Watanabe sold 19,833 shares at ~$25.50 (≈ $505,742). Todd Watanabe Form 4
  • Patrick Burnett reported two sales (3,675 shares at $25.50 and 9,794 shares at $25.81; combined ≈ $346,496). Patrick Burnett Form 4

  About Arcutis Biotherapeutics

  Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

  In August 2022, Arcutis received U.S.

  Recommended Stories

  • Five stocks we like better than Arcutis Biotherapeutics
  • The day the gold market broke
  • Buy this Gold Stock Before May 2026
  • Trump Planning to Use Public Law 63-43: Prepare Now
  • Forget AI, This Will Be the Next Big Tech Breakthrough
  • What a Former CIA Agent Knows About the Coming Collapse